Navigation Links
BellBrook Labs Launches New Turn Key Methyltransferase Assay Kit for Oncogenic Histone Methyltransferase EZH2
Date:8/28/2013

Madison, WI (PRWEB) August 28, 2013

BellBrook Labs is continuing their successful collaboration with Reaction Biology to accelerate epigenetics drug discovery with the launch of a new Transzyme Methyltransferase Assay kit for histone methyltransferase EZH2. The Transzyme EZH2 kit combines all of the required EZH2 enzyme reaction components and BellBrook’s Transcreener EPIGEN Methyltransferase Assay detection reagents into a well-defined kit that is pre-calibrated to produce HTS-quality data. With the addition of EZH2, the expanding line of Transzyme Methyltransferase Assays now numbers fourteen, including DOT1L, G9a, MLL4, PRMT1, PRMT3 SET7/9, SET8, SUVH391 and DNMT1. By eliminating the need for sourcing and testing of reagents from different vendors and trouble-shooting to optimize assay performance, the new Transzyme kits should accelerate the pursuit of promising epigenetic therapeutic strategies for cancer and other diseases.

Methyltransferases are key players in epigenetic control of gene expression and have become the targets of intensive public and private drug discovery efforts. Unfortunately, the first step in developing epigenetic drugs – identification of specific inhibitors for target enzymes – has been plagued by problems in getting methyltransferase enzymes to function correctly in the HTS assays used to detect their activity. To eliminate this hurdle, BellBrook Labs and Reaction Biology partnered last year to develop the Transzyme Methyltransferase Assay kits as complete solutions for inhibitor screening and profiling with purified methyltransferases enzymes.

EZH2 is a complex of five different proteins that act in concert to catalyze mono-, di- and tri-methylation of Histone 3 at Lys 27. The tri-methyl H3K27 mark causes transcriptional silencing of several tumor suppressors, and overexpression, amplification and somatic mutations have all been identified as mechanisms for the involvement of EZH2 in tumorigenesis. The new Transzyme EZH2 Assay kit is designed to accelerate efforts to develop selective EZH2 inhibitors using high throughput screening of small molecule libraries. The kit includes purified EZH2 from Reaction Biology, Histone H3 substrate, optimized buffer and the Transcreener EPIGEN Methyltransferase Assay reagents in a turn-key kit that has been pre-calibrated to produce HTS-quality assay windows.

About BellBrook Labs. BellBrook Labs is dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions for enzymes and phenotypic assays. The company’s Transcreener® HTS enzyme assays, used by all of the major pharmaceutical companies, make it easy to screen thousands of different enzymes, including validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. The iuvo™ Microconduit Array technology and assay screening service are based on a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology.

About Reaction Biology. Reaction Biology Corporation (“RBC”) is a premier provider of in vitro enzyme activity assays for HTS and profiling. Serving over 200 customers worldwide, RBC specializes in optimizing nanoliter scale assaying methods, allowing for high quality data with fast turnaround and economical pricing. RBC offers gold-standard radioisotope based assays in the Kinase, Methyltransferase, and HAT enzyme classes, as well as a full suite of HDAC/SIRT assays. RBC also now provides an expanding line of active, human recombinant HMTs, including some exclusive complexes. Compound libraries, custom assay development, discovery partnerships and cell-based assays are also part of RBC’s portfolio of services. Visit RBC’s website for more information: http://www.reactionbiology.com.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11063055.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BellBrook Labs Strengthens Ties with Cambio for Distribution of Transcreener HTS Assays in the UK
2. BellBrook Labs and BMG Labtech to Offer Webinar on Integrated Platform for Screening Kinases and Methyltransferases
3. BellBrook Labs Launches Four New Turn-Key Methyltransferase Assay Kits
4. BellBrook Labs and Tecan Offer Webinar on Screening Epigenetic Targets
5. BellBrook Labs Launches Second Generation Transcreener EPIGEN Methyltransferase Assay to Acclerate Epigenetic Drug Discovery
6. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
7. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
8. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
9. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
10. Neogen Launches Fully Quantitative Lateral Flow Test for DON
11. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , February 4, 2016 - New FDA action ... - New FDA action date of July 22, ... July 22, 2016   - ... in the past decade indicated for the treatment of signs and symptoms of ... has the potential to be the only product approved in the U.S. in ...
(Date:2/4/2016)... Beike Biotechnology, the Shenzhen ... ceremony in late 2015 to mark their successful combined ... --> --> The ... Cell Therapy" was hosted by the Shenzhen Cell Bank ... of Beike Biotechnology Co., Ltd. Shenzhen,s ...
(Date:2/4/2016)... EDISON, N.J. , Feb. 4, 2016 ... company focused on the development and commercialization of targeted ... BIO CEO & Investor Conference 2016, to be held ... and Source Capital Group,s 2016 Disruptive Growth & Healthcare ... on February 10-11, 2016. James Sapirstein ...
(Date:2/4/2016)... 4, 2016 Strasbourg, France ... --> Strasbourg, France , to the ... PharmaVentures is pleased to announce that it acted as an ... unit in Strasbourg, France , to the ... --> --> Transgene (Euronext: TNG), a member ...
Breaking Biology Technology:
(Date:2/1/2016)... 2016  Today, the first day of American Heart ... develop a first of its kind workplace health solution ... In the first application of Watson ... ), and Welltok will create a new offering that ... analytics, delivered on Welltok,s health optimization platform. The effort ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 31, 2015. --> --> ... percent compared to the comparable quarter last year to $470.5 million. ... million, or $0.93 per diluted share. --> ... of fiscal 2016 grew 9 percent over the prior year period ...
(Date:1/25/2016)...   Unisys Corporation (NYSE: UIS ) today announced ... International Airport, New York City , to help ... to enter the United States using passports ... pilot testing of the system at Dulles last year. The ... during January 2016. --> pilot testing of the ...
Breaking Biology News(10 mins):